secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2022-03-21T23:59:59+00:00
Accession:  0001193125-22-080529
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC discontinues ORIC-101 after Phase 1b failures; cash runway extended to 2H 2024
--------------------------------------------------------------------------------

- ORIC-101 discontinued after interim Phase 1b analyses showed insufficient activity; median PFS 3.7 months in prostate, 1.9 months in pancreatic cohorts.
- Focus shifts to three single-agent Phase 1b programs: ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2), ORIC-944 (prostate); initial data expected 1H 2023.
- Cash and investments $280.4M as of Dec 31, 2021; cash runway extended into second half of 2024 following ORIC-101 discontinuation.
- Q4 2021 R&D expenses $16.7M (vs $12.1M Q4 2020); G&A $6.1M (vs $4.3M); increases driven by program advancement and public company costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312522080529/0001193125-22-080529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312522080529/d323230d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-080529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer